Bipartisan Support For AdvaMed’s Legislative Priorities, Whitaker Says
Executive Summary
AdvaMed’s Scott Whitaker and Michael Minogue outlined the trade group’s legislative goals for the rest of the year, chief among them regulatory oversight for lab-developed tests.
You may also be interested in...
LDT Rule Will Have Massive Impact, Analysts Say; Fundamental Questions Remain
Stakeholders are still processing the US FDA’s proposed rule that would place lab-developed tests under its regulatory purview. While only time will tell what it all means, it is already clear that the agency’s action, if finalized, will significantly affect the healthcare industry and above all patients.
Pass VALID Act Now, Groups Urge Lawmakers
Diverse voices across medtech are urging US lawmakers to include the VALID Act as part of the year-end omnibus package. Advocates say the legislation would create a uniform standard for diagnostics.
US FDA Implementing Hybrid Work Policy In January
Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.